• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Vaxigrip Tetra
    / Medici

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Pre-filled Syringe (solution for injection)

    1 X 0.5 ml

    not in the basket chart 67820

    Related information


    Based on clinical experience with the trivalent vaccine, annual revaccination with influenza vaccine is recommended given the duration of immunity provided by the vaccine and because circulating strains of influenza virus might change from year to year.
    Adults: One dose of 0.5 ml.
    Paediatric population
    Children from 6 months to 17 years of age: One dose of 0.5 ml.
    For children less than 9 years of age who have not previously been vaccinated, a second dose of 0.5 ml should be given after an interval of at least 4 weeks.
    Children less than 6 months of age: The safety and efficacy of this vaccine have not been established. No data are available.
    Method of administration: The vaccine should be given by intramuscular or subcutaneous injection.


    Indicated for active immunization of adults and children from 6 months of age and older for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine.
    The use of this formulation should be based on official recommendations.


    Hypersensitivity to the active substances, to any of the excipients, or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), neomycin, formaldehyde and octoxinol-9.
    Vaccination should be postponed in case of moderate or severe febrile disease or acute disease.

    Special Precautions

    As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.
    This vaccine should under no circumstances be administered intravascular.
    As with other vaccines administered intramuscularly, the vaccine should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.
    Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent injury from fainting and manage syncopal reactions.
    This vaccine is intended to provide protection against those strains of influenza virus from which the vaccine is prepared.
    As with any vaccine, vaccination with this vaccine may not protect all vaccines.
    Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.
    See prescribing information for full details.

    Side Effects

    Headache, myalgia, and malaise.
    See prescribing information for full details.

    Drug interactions

    No interaction studies have been performed with this vaccine.

    Pregnancy and Lactation

    Pregnancy: Inactivated influenza vaccines can be used in all stages of pregnancy. See prescribing information for full details.
    LactationThis vaccine may be used during breastfeeding.


    Not documented for this vaccine. Cases of administration of more than the recommended dose (overdose) have been reported.

    Important notes

    Compatibility: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

    Sanofi Pasteur